123 related articles for article (PubMed ID: 32990096)
1. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus.
Orime K; Terauchi Y
Expert Opin Pharmacother; 2020 Dec; 21(17):2101-2114. PubMed ID: 32990096
[TBL] [Abstract][Full Text] [Related]
2. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Jain R
Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
[TBL] [Abstract][Full Text] [Related]
3. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Cobble ME; Frederich R
Cardiovasc Diabetol; 2012 Jan; 11():6. PubMed ID: 22248301
[TBL] [Abstract][Full Text] [Related]
4. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
Dore FJ; Domingues CC; Ahmadi N; Kundu N; Kropotova Y; Houston S; Rouphael C; Mammadova A; Witkin L; Khiyami A; Amdur RL; Sen S
Cardiovasc Diabetol; 2018 May; 17(1):65. PubMed ID: 29724198
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.
Men P; Li XT; Tang HL; Zhai SD
PLoS One; 2018; 13(5):e0197321. PubMed ID: 29787616
[TBL] [Abstract][Full Text] [Related]
6. Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.
Saine ME; Carbonari DM; Newcomb CW; Nezamzadeh MS; Haynes K; Roy JA; Cardillo S; Hennessy S; Holick CN; Esposito DB; Gallagher AM; Bhullar H; Strom BL; Lo Re V
BMC Pharmacol Toxicol; 2015 Apr; 16():8. PubMed ID: 25889498
[TBL] [Abstract][Full Text] [Related]
7. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Toh S; Hampp C; Reichman ME; Graham DJ; Balakrishnan S; Pucino F; Hamilton J; Lendle S; Iyer A; Rucker M; Pimentel M; Nathwani N; Griffin MR; Brown NJ; Fireman BH
Ann Intern Med; 2016 Jun; 164(11):705-14. PubMed ID: 27110660
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.
Iqbal N; Parker A; Frederich R; Donovan M; Hirshberg B
Cardiovasc Diabetol; 2014 Feb; 13():33. PubMed ID: 24490835
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies.
Davidson JA
J Manag Care Pharm; 2014 Feb; 20(2):120-9. PubMed ID: 24456313
[TBL] [Abstract][Full Text] [Related]
10. Glucagon and heart in type 2 diabetes: new perspectives.
Ceriello A; Genovese S; Mannucci E; Gronda E
Cardiovasc Diabetol; 2016 Aug; 15(1):123. PubMed ID: 27568179
[TBL] [Abstract][Full Text] [Related]
11. New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.
von Lewinski D; Kolesnik E; Wallner M; Resl M; Sourij H
Biomed Res Int; 2017; 2017():1253425. PubMed ID: 28894748
[TBL] [Abstract][Full Text] [Related]
12. Saxagliptin, a selective dipeptidyl peptidase-4 inhibitor, alleviates somatic cell aneugenicity and clastogenicity in diabetic mice.
Attia SM; Ahmad SF; Nadeem A; Attia MSM; Ansari MA; Ashour AE; Albekairi NA; Al-Hamamah MA; Alshamrani AA; Bakheet SA
Mutat Res Genet Toxicol Environ Mutagen; 2023; 892():503707. PubMed ID: 37973297
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
Wheeler DC; James J; Patel D; Viljoen A; Ali A; Evans M; Fernando K; Hicks D; Milne N; Newland-Jones P; Wilding J;
Diabetes Ther; 2020 Dec; 11(12):2757-2774. PubMed ID: 32996085
[TBL] [Abstract][Full Text] [Related]
14. Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
Werida R; Kabel M; Omran G; Shokry A; Mostafa T
Diabetes Res Clin Pract; 2020 Dec; 170():108473. PubMed ID: 33002553
[TBL] [Abstract][Full Text] [Related]
15. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
[TBL] [Abstract][Full Text] [Related]
16. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
[TBL] [Abstract][Full Text] [Related]
17. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
[TBL] [Abstract][Full Text] [Related]
18. Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial.
Scheffer M; Driessen-Waaijer A; Hamdani N; Landzaat JWD; Jonkman NH; Paulus WJ; van Heerebeek L
ESC Heart Fail; 2020 Dec; 7(6):4478-4487. PubMed ID: 33073523
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control.
Mohsen M; Elberry AA; Mohamed Rabea A; Abdelrahim MEA; Hussein RRS
Int J Clin Pract; 2021 Mar; 75(3):e13769. PubMed ID: 33068301
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
